Kazia Therapeutics Limited 已设定明确目标,计划在2026年年底前完成12名三阴性乳腺癌(TNBC)患者的入组工作。这项临床研究的顶线数据预计将在2027年初揭晓,标志着该药物研发项目的一个重要里程碑。
Kazia Therapeutics Limited 已设定明确目标,计划在2026年年底前完成12名三阴性乳腺癌(TNBC)患者的入组工作。这项临床研究的顶线数据预计将在2027年初揭晓,标志着该药物研发项目的一个重要里程碑。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.